Evaxion Biotech AS (EVAX)
3.72
-0.11
(-2.87%)
USD |
NASDAQ |
May 17, 16:00
3.72
0.00 (0.00%)
After-Hours: 20:00
Evaxion Biotech Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2022 | -0.30M |
| March 31, 2022 | 7.738M |
| December 31, 2021 | 24.65M |
| September 30, 2021 | -0.065M |
| June 30, 2021 | -0.035M |
| Date | Value |
|---|---|
| March 31, 2021 | 25.25M |
| December 31, 2020 | 2.374M |
| September 30, 2020 | 6.479M |
| June 30, 2020 | -0.018M |
| March 31, 2020 | -0.018M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.30M
Minimum
Jun 2022
25.25M
Maximum
Mar 2021
6.606M
Average
1.178M
Median
Cash from Financing (Quarterly) Benchmarks
| DBV Technologies SA | -0.062M |
| Ascendis Pharma A/S | 20.01M |
| Cellectis SA | 41.58M |
| Adaptimmune Therapeutics PLC | 29.24M |
| Akari Therapeutics PLC | -- |
Cash from Financing (Quarterly) Related Metrics
| Free Cash Flow Yield | -241.0% |